Tacrocord 0.5mg Capsule

Current price is: ₹170.89. Original price was: ₹216.93.

You saved ₹46.04 (21%)

Brand Name: Tacrocord
Category: Transplant
Manufacturer: Concord Drugs Ltd
Composition: Tacrolimus
Minimum Order Quantity: 12

Tacrocord 0.5mg Capsule is an immunosuppressant used to prevent organ rejection in patients who have undergone a kidney, liver or heart transplant. Tacrolimus is the active ingredient in Tacrocord 0.5mg Capsule. It suppresses the immune system so that it does not attack the transplanted organ.

Tell your doctor if you have diabetes, high blood pressure, or problems with your liver, kidneys, or heart before you take this medicine. Tell them if you are taking any other medicines. Because immunosuppressants may increase your risk of skin cancer, limit your exposure to the sun and UV light.

Product Description

Tacrocord 0.5mg Capsule is an immunosuppressant used to prevent organ rejection in patients who have undergone a kidney, liver or heart transplant. Tacrolimus is the active ingredient in Tacrocord 0.5mg Capsule. It suppresses the immune system so that it does not attack the transplanted organ.


Uses of Tacrocord 0.5mg Capsule:

Prevention of organ rejection in transplant patients (kidney, liver, or heart transplants)


How does Tacrocord 0.5mg Capsule work?

Tacrolimus inhibits the enzyme calcineurin, which is involved in T-cell activation of the immune system. Tacrolimus acts by blocking this pathway and thus decreasing the immune response to prevent organ rejection.


How to Use & Dosage

Swallow the capsule whole with a glass of water. Do not crush or chew. Usually taken once daily on an empty stomach in the morning.

Tacrolimus is available in different forms and should be taken as prescribed. Immediate-release capsules are usually taken twice daily and extended-release formulations are taken once daily on an empty stomach. Take tacrolimus at the same time each day as your doctor tells you.

Do not open, chew or crush extended-release capsules. Swallow whole with a glass of water. Immediate-release capsules should not be opened or crushed.


Possible Side Effects:

  • Tremors
  • Rash
  • Headache
  • Nausea
  • Vomiting
  • Dizziness
  • Fatigue
  • Diarrhea
  • High blood pressure
  • Kidney dysfunction
  • High blood sugar levels

Safety Advise:

Kidney

Tacrolimus can be nephrotoxic. Monitor kidney function regularly. Discuss with your healthcare provider.

Liver

Tacrolimus can cause liver impairment so liver function should be monitored regularly. Talk to your doctor.

Pregnancy

Tacrocord should be used during pregnancy only if clearly needed. Please speak with your healthcare provider.

Breastfeeding

It is probably not safe to use a Tacrocord 0.5mg Capsule when you are nursing a baby. Speak to your doctor.

Drink.

Do not drink alcohol while taking a Tacrocord 0.5mg Capsule. Please consult your doctor.


Storage Instructions:

Store Tacrocord capsules at a temperature of 15°C to 30°C (59°F to 86°F). Store the capsules in the original container, and keep them away from light and moisture. Do not let children reach it.

Tacrolimus is available in different forms and should be taken as prescribed. Immediate-release capsules are usually taken twice daily and extended-release formulations are taken once daily on an empty stomach. Take tacrolimus at the same time each day as your doctor tells you.

Do not open, chew or crush extended-release capsules. Swallow whole with a glass of water. Immediate-release capsules should not be opened or crushed.


References

  1. Tripathi KD. Immunosuppressive Drugs. In: Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019.
  2. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Immunosuppressants, Tolerogens, and Immunostimulants. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
  3. Astellas Pharma US, Inc. Prograf (tacrolimus) capsules, injection: full prescribing information, including Boxed Warning. Northbrook, IL: Astellas Pharma US, Inc.; 2020.
  4. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant International. 2000;13(5):313-326.
  5. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623-628.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.